Targeting, not flooding.
Current ocular therapies lose up to 95% of the drug before it reaches the target. glEYEco engineers glycan-targeting delivery systems that selectively bind to diseased tissue and stay there.
"75% of vision loss is preventable with early intervention."
Canadian Association of Optometrists
The Problem
Standard ocular treatments can't localize to inflamed tissue or remain there long enough. Up to 95% of a topical dose drains into the nasolacrimal duct almost instantly.
Glycan-Targeting Binding
An engineered binding domain that selectively adheres to disease-altered glycans on the ocular surface. It doesn't just deliver, it finds.
Hydrogel Delivery
A hyaluronic acid hydrogel that protects, releases, and increases retention. Bio-compatible. Moisturizes. Repairs the tear film.
Modular Fusion Protein
Three domains: binding, therapeutic, enhancer, assembled into one modular platform. The binding domain targets. The therapeutic domain treats. The enhancer domain extends retention. One system, multiple diseases.
Better treatment
within patient reach.
Low Manufacturing Cost
Sustainable microbial bioproduction keeps costs down. Hydrogel contact lens delivery eliminates repeated injections and clinical waste.
Platform, Not Product
The modular design means we can swap therapeutic domains to address different conditions. Same platform, new targets.
Get Involved
We're looking for research partners, mentors, and supporters. If what we're building matters to you, reach out.